MOUNTAIN VIEW, Calif., Oct. 31, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) announced today that a newly-published study demonstrated Qsymia ® (phentermine and topiramate extended-release) capsules CIV produced significantly greater weight loss, and at lower doses, compared to phentermine or topiramate administered as monotherapies in obese adults. Among patients taking the once-daily extended-release formulation, Qsymia was generally well tolerated and improved blood pressure. In this study, the effect of Qsymia on heart rate was similar to placebo.
Newly Published Study Finds Qsymia Achieves Greater Weight Loss At Lower Doses Than Either Of Its Components As Monotherapy
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.